BioSpecifics Technologies Corp (NASDAQ:BSTC) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

A number of other brokerages have also commented on BSTC. Zacks Investment Research lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a research note on Monday, May 15th. HC Wainwright set a $72.00 price target on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a research note on Thursday, August 10th.

BioSpecifics Technologies Corp (BSTC) traded up 0.15% on Friday, reaching $45.31. 19,734 shares of the company’s stock were exchanged. The company has a market cap of $324.60 million, a PE ratio of 27.80 and a beta of 1.76. The firm’s 50 day moving average price is $49.02 and its 200 day moving average price is $51.60. BioSpecifics Technologies Corp has a 52-week low of $35.79 and a 52-week high of $58.79.

WARNING: “BioSpecifics Technologies Corp (BSTC) Lowered to Strong Sell at BidaskClub” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/19/biospecifics-technologies-corp-bstc-lowered-to-strong-sell-at-bidaskclub.html.

Several institutional investors have recently bought and sold shares of BSTC. Bank of America Corp DE increased its position in BioSpecifics Technologies Corp by 122.6% in the first quarter. Bank of America Corp DE now owns 2,489 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,371 shares during the last quarter. US Bancorp DE increased its position in BioSpecifics Technologies Corp by 1.1% in the second quarter. US Bancorp DE now owns 3,455 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 36 shares during the last quarter. American International Group Inc. increased its position in BioSpecifics Technologies Corp by 7.1% in the first quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 222 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in BioSpecifics Technologies Corp by 16.2% in the first quarter. Public Employees Retirement System of Ohio now owns 3,674 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 513 shares during the last quarter. Finally, CAPROCK Group Inc. acquired a new position in BioSpecifics Technologies Corp during the second quarter worth about $206,000. 54.81% of the stock is currently owned by institutional investors.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.